📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
31 announcements match the current filters (relevance ≥ 5).
Akums Drugs Declares ₹3 Total Dividend for FY26; Record Date Set for July 03
Akums Drugs and Pharmaceuticals has recommended a total dividend of ₹3.00 per share for FY26, which includes a ₹1.00 final dividend and a ₹2.00 special dividend. The board has fixed July 03, 2026, as the record date to determine shareholder eligibility for this payout. While the company approved its FY26 audited financial results, the statutory auditors highlighted an ongoing Income Tax search and seizure matter where a show-cause notice has been recently received. Additionally, the company announced a leadership change in its HR department with the appointment of Mr. V Jagannathan as President - HR.
Key Highlights
Recommended a total dividend of ₹3.00 per share, representing 150% of the ₹2 face value.
Set July 03, 2026, as the record date for the final and special dividend payments.
Auditors raised an 'Emphasis of Matter' regarding a show-cause notice from the Income Tax Department.
Appointed Mr. V Jagannathan as President – HR, effective May 14, 2026.
The 22nd Annual General Meeting (AGM) is scheduled for July 10, 2026.
👀 What to Watch
Investors should track the July 03 record date to qualify for the ₹3 dividend payout. However, caution is advised regarding the unresolved Income Tax search and seizure proceedings which could impact future financials.
Akums Drugs Recommends ₹3 Total Dividend per Share and Approves FY26 Financial Results
Akums Drugs and Pharmaceuticals has approved its audited financial results for the fiscal year ended March 31, 2026. The Board has recommended a total dividend of ₹3.00 per equity share, comprising a ₹1.00 final dividend and a ₹2.00 special dividend. The record date for dividend eligibility is fixed for July 03, 2026. Notably, the auditors have highlighted an ongoing Income Tax search and seizure matter from 2025, for which the company recently received a show-cause notice.
Key Highlights
Recommended a total dividend of ₹3.00 per share (150% of ₹2 face value), including a ₹2.00 special dividend.
Fixed July 03, 2026, as the record date for dividend payment, subject to shareholder approval.
Appointed Mr. V Jagannathan as President – HR (Senior Management) effective May 14, 2026.
Auditors issued an 'Emphasis of Matter' regarding an Income Tax search and seizure operation and a recent show-cause notice under Section 158BC.
The 22nd Annual General Meeting (AGM) is scheduled for July 10, 2026.
👀 What to Watch
Investors should balance the positive news of a ₹3 dividend with the regulatory risk associated with the ongoing Income Tax investigation. Monitor future disclosures regarding the show-cause notice as the financial impact is currently unascertainable.
Akums Subsidiary Acquires 4,050 Sq. Mtr Industrial Plot in Haridwar for Expansion
Akums Drugs and Pharmaceuticals' wholly-owned subsidiary, Pure and Cure Healthcare Private Limited, has executed a lease deed for an industrial plot in Haridwar, Uttarakhand. The plot measures approximately 4,050 square meters and includes both land and building. This acquisition is strategically significant as the plot is adjacent to the subsidiary's existing manufacturing facility. The move is aimed at supporting and scaling up the company's business operations in the region.
Key Highlights
Wholly-owned subsidiary Pure and Cure Healthcare executed a lease deed for a 4,050 Sq. Mtr industrial plot
The plot is located at IIE SIDCUL, Haridwar, adjacent to the subsidiary's existing manufacturing facility
The acquisition includes both land and building to support future business operations
The lease deed was executed on April 28, 2026, as per the regulatory filing
👀 What to Watch
Investors should view this as a positive operational expansion that could lead to increased production capacity. Monitor the company's upcoming capital expenditure plans to see how this facility will be integrated into their manufacturing workflow.
Akums Drugs Reaffirmed AA (Stable) Rating; New A1+ Assigned for Rs 200 Cr Commercial Paper
ICRA has reaffirmed Akums Drugs and Pharmaceuticals' long-term rating at AA (Stable) and assigned a top-tier A1+ rating for its proposed Rs 200 crore commercial paper programme. The company maintains an exceptionally strong financial profile with a total debt-to-OPBDITA ratio of just 0.2x and cash reserves of Rs 1,654.4 crore as of September 2025. While the core CDMO business grew 7% YoY in 9M FY2026, the company continues to face margin pressure in its API and trade generics segments. A significant EUR 100 million upfront payment from a European contract has further bolstered liquidity.
Key Highlights
ICRA reaffirmed AA (Stable)/A1+ ratings and assigned a new A1+ rating for Rs 200 crore Commercial Paper.
Strong liquidity position with cash and equivalents of Rs 1,654.4 crore against a minimal debt of Rs 90.3 crore.
CDMO segment generated Rs 2,533 crore in 9M FY2026, benefiting from 11% volume growth.
Total Debt/OPBDITA stands at a healthy 0.2 times with an interest coverage ratio of 5.3 times.
Company received EUR 100 million upfront as part of a EUR 200 million long-term contract with a European customer.
👀 What to Watch
The reaffirmed high credit rating and robust cash position confirm the company's financial stability and low default risk. Investors should monitor the scale-up of the export business and the potential turnaround of the loss-making API segment.
Akums Q3 FY26 Revenue Up 14.8% to ₹1,160 Cr; CDMO Segment Grows 16.3%
Akums Drugs and Pharmaceuticals reported a strong Q3 FY26 with operating revenue rising 14.8% YoY to INR 1,160 crores, primarily driven by a 16.3% growth in its core CDMO business. EBITDA grew 21% YoY to INR 147 crores, with margins expanding to 12.7% despite continued pricing pressure in the API segment. The company maintains a massive cash surplus of INR 1,573 crores and is actively evaluating M&A opportunities to complement its existing business. International branded formulations showed significant recovery, growing 120% sequentially to INR 50 crores.
Key Highlights
Consolidated revenue increased 14.8% YoY to INR 1,160 crores, with CDMO revenue reaching INR 916 crores.
Operating EBITDA rose 21% YoY to INR 147 crores, while PAT stood at INR 68 crores after a one-time labour code impact of INR 18.2 crores.
International branded formulation revenue surged 120% QoQ to INR 50 crores due to demand recovery in key markets.
Maintained a strong liquidity position with a cash surplus of INR 1,573 crores and free cash flow of INR 944.5 crores.
European expansion is on track with EU GMP accreditation received for Plant 2 and supplies already commenced from Plant 1.
👀 What to Watch
Investors should monitor the company's deployment of its INR 1,573 crore cash pile for strategic acquisitions and the ramp-up of its European CDMO operations. The stock remains a strong play on the domestic outsourcing theme given its robust volume growth and margin expansion in the core CDMO segment.
Akums Drugs Q3 FY26 Revenue Up 14.8% to ₹1,160 Cr; CDMO Segment Grows 16.3%
Akums Drugs reported a strong Q3 FY26 with operating revenue reaching ₹1,160 crores, a 14.8% YoY increase, primarily driven by 16.3% growth in the core CDMO segment. EBITDA grew 21% YoY to ₹147 crores, with margins improving to 12.7% despite continued pricing pressure in the API business. The company maintains a robust cash surplus of ₹1,573 crores and is progressing on international expansions, including EU GMP accreditation for its oral liquids facility. Profit after tax stood at ₹68 crores, which includes a one-time labor code impact of ₹18.2 crores.
Key Highlights
Consolidated revenue grew 14.8% YoY to ₹1,160 crores, led by double-digit volume growth in CDMO.
EBITDA increased 21% YoY to ₹147 crores with margins expanding 65 bps to 12.7%.
CDMO segment revenue reached ₹916 crores, while API losses narrowed sequentially to ₹7 crores.
Company holds a significant cash surplus of ₹1,573 crores and generated free cash flow of ₹944.5 crores.
Plant 2 received EU GMP accreditation; European supplies for a major contract are expected to start in FY28.
👀 What to Watch
Investors should focus on the company's ability to deploy its ₹1,573 crore cash surplus for inorganic growth and the upcoming ramp-up of international projects. The core CDMO business remains robust, and the narrowing of API losses suggests improving operational efficiency.
Akums Q3 FY26: Revenue Up 14.8% YoY to Rs 1,160 Cr, Adj PAT Jumps 29.5%
Akums Drugs and Pharmaceuticals reported a robust Q3 FY26 performance with revenue increasing 14.8% YoY to Rs 1,160 crore. The core CDMO business grew over 16% while Adjusted EBITDA rose 21% to Rs 147 crore, reflecting improved capacity utilization and margin expansion to 12.7%. Adjusted PAT saw a significant jump of 29.5% YoY to Rs 86 crore. Additionally, the company secured key regulatory approvals from EU GMP and UK MHRA, strengthening its position for expansion into regulated global markets.
Key Highlights
Revenue increased 14.8% YoY to Rs 1,160 Cr, driven by strong CDMO volumes and international demand.
Adjusted EBITDA grew 21% YoY to Rs 147 Cr, with margins improving to 12.7% from 12.0% in Q3 FY25.
Adjusted PAT surged 29.5% YoY to Rs 86 Cr, while 9M FY26 PAT reached Rs 193 Cr.
Secured EU GMP certifications for two facilities and first UK MHRA approval for Rivaroxaban tablets.
International branded formulation segment revenue more than doubled on a sequential basis.
👀 What to Watch
The strong earnings growth and regulatory breakthroughs in regulated markets like the EU and UK are positive indicators. Investors should monitor the company's ability to maintain this momentum in international markets and the turnaround in the API segment.
Akums Drugs Q3 FY26 PAT Jumps 29.5% to ₹86 Cr; CDMO Revenue Up 16.3%
Akums Drugs reported a strong Q3 FY26 with consolidated revenue growing 14.8% YoY to ₹1,160 crore, driven primarily by its core CDMO segment. Adjusted PAT for the quarter rose significantly by 29.5% to ₹86 crore, supported by operating leverage and improved capacity utilization of 47%. While the API and Trade Generics segments continue to face pricing pressures, the company is seeing demand recovery in international branded formulations. Management highlighted that global expansion projects in Europe and Zambia remain on track for future revenue contributions.
Key Highlights
Q3 FY26 Revenue grew 14.8% YoY to ₹1,160 Cr, led by a 16.3% surge in the core CDMO business.
Adjusted PAT for Q3 FY26 rose 29.5% YoY to ₹86 Cr, while Adjusted EBITDA increased 21% to ₹147 Cr.
Overall capacity utilization improved to 47% in Q3 FY26, driven by strong double-digit volume growth.
API segment losses narrowed to ₹7 Cr in Q3 FY26 from ₹11 Cr in Q3 FY25 due to cost optimization.
International Branded Formulation revenue increased 18% YoY to ₹50 Cr with a healthy 25.8% EBITDA margin.
👀 What to Watch
Investors should focus on the strong volume growth in the core CDMO segment and the successful narrowing of losses in the API business. The company's progress toward European and African market entries provides a positive long-term outlook.
Akums Drugs Q3 Standalone Revenue Up 18% Q-o-Q to ₹3,656M; PAT Declines 31% Y-o-Y
Akums Drugs and Pharmaceuticals reported a standalone revenue of ₹3,656.06 million for Q3 FY26, showing a healthy sequential growth of 18.2% from Q2. However, Net Profit (PAT) at ₹281.14 million declined by 31.7% year-on-year, impacted by rising expenses and an exceptional loss of ₹38.08 million. The company has successfully utilized 100% of its ₹6,373.70 million IPO proceeds for debt repayment and working capital. Investors should remain cautious regarding the ongoing Income Tax search proceedings, which are yet to reach a final conclusion.
Key Highlights
Standalone Revenue from operations grew 18.2% Q-o-Q to ₹3,656.06 million.
Net Profit (PAT) stood at ₹281.14 million, down from ₹411.68 million in the same quarter last year.
Reported an exceptional item loss of ₹38.08 million during the quarter ended December 2025.
Total expenses increased to ₹3,585.35 million compared to ₹3,063.58 million in Q3 FY25.
IPO proceeds of ₹6,373.70 million have been fully utilized as of December 31, 2025.
👀 What to Watch
Investors should monitor the company's ability to recover margins which have seen year-on-year compression despite revenue growth. The ongoing Income Tax department's search and seizure proceedings remain a key regulatory risk to track.
Akums Drugs Secures EU-GMP Certification for Two Haridwar Facilities; Valid Until 2028
Akums Drugs and Pharmaceuticals has received European GMP certifications for its Plant 1 and Plant 2 located in Haridwar from the Bulgarian Drug Agency. Plant 1 received a renewal, while Plant 2 achieved its first-ever EU-GMP certification, both valid for three years until October 2028. This milestone allows the company to export tablets, capsules, and oral liquids to EU-regulated markets and other regions following similar standards. Crucially, Plant 2 will now begin servicing a European CDMO contract that was signed in December 2024.
Key Highlights
EU-GMP certification granted by Bulgarian Drug Agency for two Haridwar-based manufacturing plants.
Plant 1 certification is a renewal, while Plant 2 receives its first-time EU-GMP approval.
Certifications are valid for a 3-year period, expiring in October 2028.
Plant 2 will service the European CDMO contract signed by the company in December 2024.
Enables supply of tablets, capsules, sachets, and oral liquid formulations to EU regulated markets.
👀 What to Watch
This is a positive development that expands the company's addressable market and validates its manufacturing standards for high-margin exports. Investors should monitor the execution of the December 2024 CDMO contract as a key revenue driver.
Akums Drugs President – Finance Rajkumar Bafna Resigns Effective Dec 31, 2025
Akums Drugs and Pharmaceuticals Limited has announced the resignation of Mr. Rajkumar Bafna from his position as President – Finance, a Senior Management Personnel role. The resignation is effective from the close of business hours on December 31, 2025. Mr. Bafna cited personal health concerns specifically related to Delhi's pollution levels as the reason for his departure. The company has accepted the resignation and is managing the transition of his responsibilities.
Key Highlights
Mr. Rajkumar Bafna, President – Finance, to step down effective December 31, 2025.
The resignation was formally tendered on December 3, 2025, and accepted by the company on December 12, 2025.
Departure is attributed to personal health issues linked to environmental conditions in Delhi.
Mr. Bafna is categorized as Senior Management Personnel (SMP) under SEBI Listing Regulations.
👀 What to Watch
Investors should monitor the company's upcoming announcements regarding the appointment of a successor to ensure continuity in financial leadership. The clear personal reason provided for the resignation mitigates concerns regarding internal corporate governance issues.
